Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (752)	2/8/2005 10:39:06 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GNVC, Yes.But it first has to close its Oct.7 downgap.<g> As you may recall, that was the day that it announced that the FDA had issued a "clinical hold" on its clinical trials of TNFerade,which is on 3 PIIs for Ca of pancreas, esophagus and rectum. The PII on BIOBYPASS,its VEGF121 which is intended to stimulate angiogenesis on heart muscle also seems to be "on hold" with the same number of patients (71) it had reported at the time of my comment on Nov.2002 Message 18256181 Since then, GNVC merged with Diacrin and are working on "cell transplantation technology" at Diacrin's premises in Mass. I am not sure how far advanced its work is with AdPEDF for wet MD, but I think it is still on PI. GNVC has been cutting its loss for the last 4Qs and the Dec.Q loss is expected to be around $0.08 vs.$0.10 in 2003 for a Yr. loss of $0.37 vs. $0.68 in 2003.It reportedly has $0.50 in cash/share and a Debt/Equity Ratio of 0.14 Insiders reportedly hold more than 30% and has a negligible short position. On Jan.20 it announced a $1.6M contract with the Department of Defense to make a malaria vaccine using its adenovector technology.(VICL is apparently no longer working on that type of vaccine.<g>) At any rate, if GNVC can manage to close above the $2.60 level it seems it could get to test its Oct.1 H at $2.78 and even its Jun.H at $3.41 stockcharts.com bigcharts.marketwatch.com Its April H at $4.40 seems too far at present.<g>(And as you may recall there is more resistance around that level since its Nov.2003 H was $4.49) bigcharts.marketwatch.com Bernard